Feb 12, 2026 FRONTEO and NB Health Laboratory Reach a Basic Agreement on Joint Research in GPCR Antibody Drug Discovery Aiming for implementation as early as FY2026 to secure discontinuous revenue opportunities
Feb 5, 2026 FRONTEO and GlyTech Launch Proof-of-Concept (PoC) for AI-Driven Drug Discovery Utilizing Drug Discovery AI Factory—which systematically identifies previously unknown correlations between diseases and target molecules based on existing literature—to explore new target molecules and indications for glycan-modification-based drug discovery
Feb 3, 2026 FRONTEO and C4U Conclude a PoC Agreement to Establish a New Drug Discovery Approach Combining “Drug Discovery AI Factory” and Next-Generation Genome Editing Technology
Jan 21, 2026 FRONTEO and TAGCyx Bio concluded a PoC feasibility agreement to explore new therapeutic targets and indications for artificial nucleic acid aptamers utilizing Drug Discovery AI Factory
Jan 7, 2026 FRONTEO and CellAxia Conclude a PoC Agreement to Improve Manufacturing Efficiency and Cellular Function of Cell Therapy Products Using Drug Discovery AI Factory
Nov 13, 2025 FRONTEO and UBE Enter Basic Agreement on Joint Research Utilizing Drug Discovery AI Factory Collaboration Aimed at Out-Licensing Innovative Drug Discovery Seeds Combining strengths in target molecule discovery and compound generation and optimization to create novel drug discovery opportunities
Sep 30, 2025 NB Health Laboratory and FRONTEO Signed PoC (Proof of Concept) Research Agreements Combining AI-Driven Drug Discovery with Antibody Drug Discovery Platform to Create Novel Antibody Drug Pipelines Targeting GPCRs
Aug 25, 2025 FRONTEO Presents Research on Exploring the Mechanism of Action of a Kampo Medicine Using the “Drug Discovery AI Factory” Building gene networks of Hochuekkito with proprietary natural language processing technology to explore scientific mechanisms
Aug 17, 2025 FRONTEO Signs Phase 2 Agreement with Daiichi Sankyo on Toxicity Information Analysis Using the Drug Discovery AI Factory Collaboration expands following validation of the “Text Analysis of Toxicology Study Reports” initiative
Aug 4, 2025 FRONTEO and NICCA Chemical Launch Co-Creation Project Utilizing the Drug Discovery AI Factory for Novel Target Discovery in the Cosmetics Field FRONTEO and NICCA Chemical Launch Co-Creation Project Utilizing the Drug Discovery AI Factory for Novel Target Discovery in the Cosmetics Field
Jul 22, 2025 FRONTEO Confirms the Cell Proliferation - Inhibitory Effect of Novel Pancreatic Cancer Target Candidates, Identified by its AI Drug Discovery Support Service "Drug Discovery AI Factory" Successfully uncovered numerous highly novel target molecule candidates in just two days, making a major advance in “target discovery”
